CVE:ADKDiagnos Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Diagnos Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.16 0.00 (0.00 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.16Now: C$0.16▼C$0.1650-Day RangeC$0.16MA: C$0.17▼C$0.1952-Week RangeC$0.10Now: C$0.16▼C$0.33Volume7,000 shsAverage Volume51,084 shsMarket CapitalizationC$9.82 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media DIAGNOS Inc. provides software-based interpretation services primarily in Canada, the United Arab Emirates, Saudi Arabia, Slovakia, and the United States. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. DIAGNOS Inc. has a collaboration agreement with ÉTS, École de technologie supérieure. The company was founded in 1998 and is headquartered in Brossard, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Diagnos. Previous Next 2.3 Community Rank Outperform VotesDiagnos has received 33 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDiagnos has received 38 “underperform” votes. (Add your “underperform” vote.)Community SentimentDiagnos has received 53.52% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Diagnos and other stocks. Vote “Outperform” if you believe ADK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDiagnos does not currently pay a dividend.Dividend GrowthDiagnos does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Diagnos insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Diagnos is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Diagnos is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiagnos has a P/B Ratio of 5.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Health Information Services Sub-IndustryN/A SectorComputer and Technology Current SymbolCVE:ADK Previous Symbol CUSIPN/A CIKN/A Webwww.diagnos.ca Phone+1-450-6788882Debt Debt-to-Equity Ratio18.56 Current Ratio4.02 Quick Ratio3.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$331,517.00 Price / Sales29.62 Cash FlowC$0.03 per share Price / Cash Flow5.33 Book ValueC$0.03 per share Price / Book5.33Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares61,366,000Market CapC$9.82 million Next Earnings Date8/26/2020 (Estimated) OptionableNot Optionable TSXV:ADK Rates by TradingView Receive ADK News and Ratings via Email Sign-up to receive the latest news and ratings for ADK and its competitors with MarketBeat's FREE daily newsletter. Diagnos (CVE:ADK) Frequently Asked Questions How has Diagnos' stock been impacted by COVID-19 (Coronavirus)? Diagnos' stock was trading at C$0.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADK stock has decreased by 27.3% and is now trading at C$0.16. View which stocks have been most impacted by Coronavirus. When is Diagnos' next earnings date? Diagnos is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for Diagnos. How were Diagnos' earnings last quarter? Diagnos Inc (CVE:ADK) posted its earnings results on Friday, June, 5th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.08 million for the quarter. View Diagnos' earnings history. Has Diagnos been receiving favorable news coverage? News articles about ADK stock have trended negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Diagnos earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days. View the latest news about Diagnos. Who are some of Diagnos' key competitors? Some companies that are related to Diagnos include Vitalhub (VHI), Novita Healthcare (NHL), Reliq Health Technologies (RHT), Induction Healthcare Group (INHC), Oneview Healthcare (ONE), 1ST Group (1ST), Emerald Clinics (EMD), ICSGlobal (ICS), Jayex Healthcare (JHL), Global Health (GLH), CardioComm Solutions (EKG), CannaOne Technologies (CNNA), CannaOne Technologies (CNONF), Corum Group (COO) and eWELLNESS HEALTHCARE (EWLL). View all competitors. What other stocks do shareholders of Diagnos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diagnos investors own include Aileron Therapeutics (ALRN), Axovant Gene Therapies (AXGT), Avinger (AVGR), Belmont Resources (BEA), BioNano Genomics (BNGO), CLEAR CHANNEL O/SH (CCO), Caladrius Biosciences (CLBS), CleanSpark (CLSK), Century Global Commodities (CNT) and Cocrystal Pharma (COCP). Who are Diagnos' key executives? Diagnos' management team includes the following people: Mr. André Larente, CEO, Pres & Exec. DirectorMr. Marc-André Massue, VP of Fin., CFO & Sec.Mr. Guillermo Moreno Robles, VP of SalesDr. Hadi Chakor Djelthia, Chief Medical Officer What is Diagnos' stock symbol? Diagnos trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ADK." How do I buy shares of Diagnos? Shares of ADK and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Diagnos' stock price today? One share of ADK stock can currently be purchased for approximately C$0.16. How big of a company is Diagnos? Diagnos has a market capitalization of C$9.82 million and generates C$331,517.00 in revenue each year. What is Diagnos' official website? The official website for Diagnos is www.diagnos.ca. How can I contact Diagnos? Diagnos' mailing address is 7005 Taschereau Blvd, Suite 340 Brossard, BROSSARD, QC J4Z 1A7, Canada. The company can be reached via phone at +1-450-6788882. This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
